RhoB Is Stabilized by Transforming Growth Factor beta  and Antagonizes Transcriptional Activation*

Michael E. Engel, Pran K. Datta, and Harold L. MosesDagger

From the Department of Cell Biology and the Vanderbilt Cancer Center, Vanderbilt University, Nashville, Tennessee 37232-6838

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Transforming growth factor beta  (TGF-beta ) is the prototype for an evolutionarily conserved superfamily of secreted factors implicated in diverse biological phenomena. The pleiotropic responses to TGF-beta are initiated by a heteromeric receptor complex that binds and phosphorylates downstream effectors. Among these, the Smads have been extensively studied. However, less attention has been directed toward alternative downstream effectors and their participation in TGF-beta signal transduction. We show that TGF-beta promotes accumulation of the labile monomeric GTPase RhoB by antagonizing its normal proteolytic destruction, presumably via the 26 S proteasome. RhoB accumulates in its isoprenylated form. Transient overexpression of wild type RhoB but not its dominant negative mutant RhoB-N19 antagonizes TGF-beta -mediated transcriptional activation. These results suggest a novel mechanism of regulation by TGF-beta and implicate RhoB as a negative regulator of TGF-beta signal transduction.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Transforming growth factor-beta (TGF-beta )1 is the prototype for a multifunctional superfamily of secreted factors. TGF-beta has been implicated in diverse phenomena including growth control, production of extracellular matrix, cell adhesion and motility, and modulation of cell phenotype (1). As such, TGF-beta has broad influence over normal growth and developmental programs and over the pathologic sequelae that arise from their dysfunction. TGF-beta communicates with the cytoplasm through a heteromeric complex composed of type I (Tbeta RI) and type II (Tbeta RII) transmembrane serine/threonine kinase receptors. Upon ligand binding, Tbeta RII transphosphorylates Tbeta RI in a highly conserved GS domain, thereby activating Tbeta RI kinase activity toward downstream effectors. Ligand binding specificity is conferred by Tbeta RII, whereas signal specificity is conferred by Tbeta RI (2).

Several studies have focused on the nature of the signal transduction machinery downstream of the TGF-beta receptor complex. Genetic approaches in Drosophila melanogaster and Caenorhabditis elegans, along with supporting biochemical evidence in Xenopus laevis and mammalian systems have implicated the Smad family of proteins in signaling by TGF-beta superfamily members. Evidence suggests that the Smads, through ligand-dependent phosphorylation and hetero-oligomerization, play crucial roles in growth and transcriptional regulation by TGF-beta (3). Other putative downstream effectors in TGF-beta signaling include FKBP12 (4), farnesyltransferase-alpha (5), and TRIP-1 (6), each identified through their specific interactions with TGF-beta receptors. However, despite extensive investigation, a clearly defined picture of the post-receptor signaling machinery for TGF-beta remains elusive.

Rho proteins, monomeric GTPases of the Ras superfamily (7), serve as molecular switches that cycle between GTP-bound (active) and GDP-bound (inactive) states. Rho proteins undergo a complex series of post-translational modifications initiated by isoprenylation of a C-terminal CAAX motif (8). Generally, Rho proteins are geranylgeranylated, although RhoB can be modified by either a geranylgeranyl or a farnesyl moiety (9). In most cases, Rho protein function requires isoprenylation (8, 10). Rho proteins regulate specific actin cytoskeletal structures, including stress fibers (RhoA/C), lamellipodia (Rac1), and filopodia (Cdc42), and make manifest the effects of growth factors and oncogenes on cell morphology (11). Additionally, Rho family members have been implicated in cell growth control as regulators of the G1/S transition and in transformation, both alone and in cooperation with oncogenic Ras (12-14). Recent evidence also suggests that Rho proteins, as regulators of the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling module, are components of the intracellular relay for transcriptional activation signals that originate from the TGF-beta receptor complex (15).

RhoB, whose primary structure is 88% identical to the Rho family prototype RhoA, has several distinguishing features. Most notably, RhoB is inducible by a variety of stimuli, including the growth factors epidermal growth factor and platelet-derived growth factor, genotoxic stresses from UV light and alkylating xenobiotics, and activated tyrosine kinases such as v-Src and v-Fps (16-18). Unlike other Rho family members, both RhoB mRNA and protein are labile, with half-lives of approximately 20 min and 2 h, respectively (18, 19). Additionally, RhoB is subject to post-translational palmitoylation as a secondary membrane localization signal following isoprenylation (20). This contrasts with other Rho proteins, for whom this role is presumably accomplished by an intrinsic polybasic domain immediately proximal to the CAAX motif. Because of a high degree of homology, it has been hypothesized that RhoB and RhoA have similar biological activities. Both proteins promote transactivation of the serum response element of the c-fos promoter (10, 21). Also, both RhoB and RhoA can potentiate the transforming activity of oncogenic Ras (13, 14, 19). However, RhoB and RhoA are localized differently in mammalian cells. Furthermore, although RhoA subcellular localization is altered in response to lysophosphatidic acid, localization of RhoB is unaffected (22). In conjunction with differences in protein stability, post-translational modifications, and inducibility by exogenous stimuli, the physiologic functions of RhoB and RhoA appear at least partially distinct.

Because of its inducibility and the previously described effects of Rho family members on TGF-beta signal transduction, we explored the influence of TGF-beta on RhoB and the subsequent influence of RhoB on TGF-beta -mediated gene expression. We demonstrate that RhoB turnover occurs via ubiquitin-mediated destruction by the 26 S proteasome and that TGF-beta exerts a stabilizing influence toward RhoB, thereby permitting its accumulation. Unlike other stimuli that induce RhoB gene transcription, TGF-beta -mediated accumulation of RhoB does not correlate with changes in RhoB mRNA levels. Furthermore, transcriptional activation of the TGF-beta -responsive reporter p3TP-Lux is antagonized by wild type RhoB in a dose-dependent manner but is not affected by its dominant inhibitory point mutant, RhoB-N19. These data suggest that TGF-beta can regulate the abundance of some cytoplasmic effectors by controlling their destruction. Additionally, these data suggest that cells enlist multiple Rho proteins to coordinate transcriptional activation signals initiated by TGF-beta .

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell Culture, Plasmids, Antibodies, and Reagents-- Mv1Lu cells, obtained from ATCC (CCL-64), and R1B(L17) cells (28), obtained from Dr. Joan Massagué, were subcultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The pcDNA3-HA:RhoB and pcDNA3-HA:RhoB-N19 were kindly provided by Dr. George Prendergast (19). Dr. Mathias Trier provided pMT107, encoding octameric, hexahistidine-tagged ubiquitin, which has been previously described (27). pGE-I and pGE-IX (23) were generously provided by Dr. Yoshiaki Monden (Banyu Pharmaceuticals, Inc., Ltd., Japan). pCMV5-Tbeta RI:HA (28) was the gift of Dr. Joan Massagué. The alpha -HA monoclonal antibody 12CA5 was obtained from Boehringer Mannheim. Remaining antibodies, including alpha -RhoB (119), alpha -RhoA (26C4), alpha -Rac1 (C-14), and alpha -Rho-GDI (C-20), were purchased from Santa Cruz Biotechnology, Inc. Donkey alpha -rabbit and donkey alpha -mouse conjugates with horseradish peroxidase were obtained from Amersham Pharmacia Biotech. TGF-beta 1 was generously provided by R & D Systems, Inc. Lovastatin, obtained from Merck, was activated by alkaline hydrolysis of its intramolecular lactone in 0.1 N NaOH/EtOH prior to use. The proteasome inhibitor leucinyl-leucinyl-norleucinal (LLnL) and cycloheximide were obtained from Sigma. Protein A-Sepharose was obtained from Amersham Pharmacia Biotech. Oligo(dT) cellulose was purchased from Collaborative Biomedical Products, Inc.

Electrophoresis and Immunoblotting of Rho Proteins-- Mv1Lu cells treated as described in figure legends were washed with ice-cold PBS and lysed by scraping into Nonidet P-40 lysis buffer (50 mM Tris, 150 mM NaCl, 1% Nonidet P-40, 10 mM EDTA, 20 µM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 5 mM NaF, 0.5 mM Na3(VO4), 5 mM N-ethylmaleimide, pH 8.0). Crude lysates were incubated at 4 °C for 15 min with agitation and clarified by centrifugation for 15 min at 4 °C. Protein concentrations determined by Bradford protein assay were used to normalize gel loading. Proteins were resolved by Tricine SDS-PAGE essentially as described (24) and electrotransferred to polyvinylidene difluoride membranes (Millipore, Inc.) in 25 mM Tris, 192 mM glycine, 20% methanol, pH 8.35. Membranes were blocked in PBS containing 0.25% gelatin and 0.05% Tween-20 and probed with primary antibody as indicated for 2 h at ambient temperature. After washing with PBS + 0.05% Tween-20, membranes were probed for 1 h with appropriate secondary antibody conjugate. Proteins were visualized by chemiluminesence detection. Scanning densitometry was performed on an Alpha Innotech IS-1000 Digital Imaging System.

Transient Assays Using p3TP Luciferase Reporter-- Mv1Lu or R1B(L17) cells in 6-well plates were transiently transfected with pcDNA-HA:RhoB, pcDNA3-HA:RhoB-N19, and pCMV5-Tbeta RI:HA by the DEAE-dextran method as shown in the legend for Fig. 5. The constitutive reporter CMV-beta gal was also included to normalize transfection efficiency. After overnight recovery in DMEM + 10% FBS, cells were incubated in DMEM + 0.2% FBS with or without 40 pM TGF-beta for 16 h. For all assays, cells were washed with ice-cold 1× PBS. Cell lysates were then prepared by rocking for 15 min in 100 mM Na2HPO4/NaH2PO4, 1% Triton X-100, 1 mM beta -mercaptoethanol, 2 mM EDTA, pH 7.8, and subsequently clarified by brief centrifugation. Luciferase and beta -galactosidase activities were measured in an Analytical Luminescence Labs Monolight 2010 luminometer. beta -Galactosidase activity was determined with the proprietary Galacton-Plus luminescent substrate/accelerator system (Tropix, Inc.) according to the manufacturer's instructions.

Northern Blot Analysis of Poly(A) RNA-- Mv1Lu cells were maintained in DMEM + 0.2% FBS for 24 h and then incubated as indicated in the legend for Fig. 2. Poly(A) RNA was purified using oligo(dT) cellulose according to standard methods (25). 4 µg of poly(A) RNA was resolved in a 1% formaldehyde-agarose gel and transferred to Hybond N+ filters. After 4 h of prehybridization (50% deionized formamide, 150 µg/ml salmon sperm DNA, 1× Denhardt's, 50 µg/ml poly(A), 0.1% SDS, 5× SSC) at 42 °C, filters were probed for 18 h with either the complete RhoB cDNA or a cyclophilin-specific probe, both 32P-labeled by random priming. Filters were washed sequentially, twice with 2× SSC + 0.1% SDS, then three times with 0.5× SSC + 0.1% SDS at 42 °C, and once in the same wash buffer at 65 °C. Results were visualized with a Molecular Dynamics, Inc. PhosphorImager 445 SI.

Reverse Transcriptase-coupled PCR-- Primers specific for mink RhoB were based upon regions of absolute nucleotide conservation from rat to human RhoB. Primer sequences were as follows: 5'-GAGAACATCCCCGAGAAGT-3' and 5'-TGCAGCAGTTGATGCAGCC-3'. A 304-bp fragment is predicted based upon the human and rat RhoB sequences. Primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the internal control, were purchased from CLONTECH, Inc. Mv1Lu cells were maintained in DMEM with 0.2% FBS. Total RNA was isolated from TGF-beta -treated or time matched, untreated controls using guanidinium isothiocyanate as described previously (26). Total RNA (0.5 µg) was reverse transcribed using an oligo(dT) primer. The resulting cDNA was amplified by PCR with RhoB-specific and GAPDH-specific primers simultaneously. PCR products were resolved in 2% agarose/0.5× TBE (1× TBE = 90 mM Tris, 90 mM borate, 2 mM EDTA, pH 8.0) gels and visualized by ethidium bromide staining and ultraviolet transillumination. The GAPDH PCR product was used to normalize gel loading. PCR parameters permitted both RhoB and GAPDH products to be analyzed within the linear range. The RhoB-specific PCR product was isolated and subjected to automated dideoxy sequencing to confirm its identity.

Determination of RhoB Half-life in Mv1Lu Cells-- Mv1Lu cells were maintained in DMEM + 10% FBS. In parallel cultures, growth medium was changed to either DMEM + 0.2% FBS or that same medium supplemented with 40 pM TGF-beta 1. Cultures were incubated in these conditions for 4 h. At the end of this 4-h incubation, corresponding to time 0, growth medium was changed to DMEM + 0.2% FBS and 30 µg/ml cycloheximide, with or without coincident 40 pM TGF-beta 1. At the indicated times, cells were lysed in Nonidet P-40 lysis buffer and clarified as above. Equivalent amounts of total cellular protein were analyzed by Tricine SDS-PAGE and RhoB-specific immunoblot analysis. Scanning densitometry was performed as above. To ensure abrogation of new RhoB synthesis during the cycloheximide chase, control cultures were maintained in M-/C- medium for 1 h then incubated for 4 h in M-/C- medium supplemented with 200 µCi/ml [35S]methionine/cysteine with or without coincident 30 µg/ml cycloheximide. Cell monolayers were washed and lysed in Nonidet P-40 lysis buffer as described above. Crude lysates were clarified by centrifugation and precleared with protein A-Sepharose. Supernatants were then incubated for 16 h with either 1 µg of RhoB-specific antibody or nonspecific rabbit serum. Immune complexes were collected with protein A-Sepharose and subjected to SDS-PAGE as described above. Labeled proteins were detected in fixed gels by autoradiography.

Determination of RhoB Ubiquitination and Turnover by the 26 S Proteasome-- Mv1Lu cells maintained in DMEM + 10% FBS were transfected by the DEAE-dextran technique with pMT107 and pcDNA3-HA:RhoB in the combinations indicated in Fig. 4. Cultures were incubated for 36 h in DMEM + 10% FBS and then switched to DMEM + 0.2% FBS with or without coincident 50 µM LLnL. After 24 h of incubation, cells were lysed in 100 mM NaH2PO4/Na2HPO4, 6 M guanidinium-HCl, 20 µM phenylmethylsulfonyl fluoride, 10 mM N-ethylmaleimide, pH 8.0, and ubiquitinated proteins purified by Ni2+/NTA-agarose chromatography essentially as described (27). Ubiquitinated proteins were resolved by Tricine SDS-PAGE and subsequently examined by RhoB-specific and HA epitope tag-specific immunoblot analysis as above. The degree of ubiquitin conjugation was estimated by mobility in SDS-PAGE relative to the nonubiquitinated RhoB protein and molecular weight markers.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

TGF-beta Promotes Accumulation of Isoprenylated RhoB-- Several stimuli have been shown to promote accumulation of RhoB mRNA (16, 17, 18). However, although more closely aligned with function, RhoB protein levels have been examined in a more limited context. We examined the abundance of RhoB, the Rho family members RhoA and Rac1, and the Rho-specific regulator Rho-GDI in Mv1Lu cells (Fig. 1A, a-d) in the presence and absence of TGF-beta . Lovastatin, which abrogates isoprenoid synthesis by inhibition of hydroxymethylglutaryl-coenzyme A reductase, was used to distinguish between prenylated (*) and nonprenylated forms based upon mobility differences in Tricine SDS-PAGE. Prenylated and nonprenylated RhoB were easily distinguished, but differentially prenylated forms of RhoA and Rac1 were not readily resolved. As anticipated, no mobility differences were noted for Rho-GDI, because it is not a prenylated protein.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 1.   TGF-beta promotes accumulation of isoprenylated RhoB in Mv1Lu cells. A, Mv1Lu cells were maintained in DMEM with 10% FBS, 0.2% FBS, or 0.2% FBS supplemented with either TGF-beta or lovastatin as indicated. Equivalent amounts of total cellular protein were resolved by Tricine SDS-PAGE. Proteins were electrotransferred to polyvinylidene difluoride membranes and probed with antibodies against RhoB (a), RhoA (b), Rac1 (c), or Rho-GDI (d). Antigens were visualized by chemiluminescent detection using appropiate secondary antibody-horseradish peroxidase conjugates. Lovastatin treatment suggests the identity of isoprenylated RhoB (*) and its unmodified precursor (see "Results"). B, Mv1Lu cells maintained in DMEM + 10% FBS were switched to DMEM + 0.2% FBS and incubated for 28 h to deplete pre-existing RhoB protein. At time 0, parallel cultures were given either DMEM + 0.2% FBS or that same medium supplemented with TGF-beta . At the times indicated, cell lysates were prepared for RhoB-specific immunoblot analysis as described under "Materials and Methods." Relative distribution between unmodified and isoprenylated RhoB was estimated by scanning densitometry. No Tx, no treatment.

Mv1Lu cells grown in a serum-rich medium express RhoB protein approximately equally divided between prenylated and nonprenylated forms. However, when switched to low serum medium, the abundance of RhoB protein decreases with time. A difference was noted in the rate of disappearance between prenylated and nonprenylated RhoB, with the latter disappearing more rapidly (Fig. 1A, a). When low serum medium is supplemented with 40 pM TGF-beta , RhoB protein levels remain elevated, and both prenylated and nonprenylated forms are noted. In contrast to Mv1Lu cells grown in a serum-rich environment, the distribution of RhoB protein between prenylated and nonprenylated forms is skewed toward the former in the presence of TGF-beta . In contrast to the dynamic nature of RhoB levels, RhoA, Rac1, and Rho-GDI levels were not significantly affected by low serum, TGF-beta , or lovastatin treatment.

To gain additional insight into the kinetics of RhoB accumulation, we examined its abundance in whole cell lysates from TGF-beta -treated or matched untreated controls, preceded by 28 h of incubation in low serum medium to deplete pre-existing RhoB protein (Fig. 1B). Again, prenylated RhoB (*) was separated from nonprenylated RhoB by differential mobility in Tricine SDS-PAGE. Total RhoB protein, separated into prenylated and nonprenylated forms is depicted in Fig. 1B by scanning densitometry of identically developed immunoblots. In comparison with consistently low levels in untreated controls, TGF-beta promoted a significant, time-dependent increase in the abundance of RhoB protein (approximately 8-10-fold). Furthermore, RhoB from TGF-beta -treated cells accumulated predominantly in the isoprenylated form, reaching 85% prenylated RhoB in the 4-h time point. In contrast, the distribution between prenylated and nonprenylated RhoB in untreated controls fell within a range of 40-60%/60-40%, similar to the distribution found in serum-rich medium and more readily apparent with longer exposure (data not shown). We also examined the relative abundance of RhoB protein and the prenylated/nonprenylated ratio in TGF-beta -treated and matched, untreated controls using the Mv1Lu-derived, TGF-beta -nonresponsive cell line R1B(L17) (28). Neither RhoB protein levels nor the prenylated/nonprenylated ratio differed in R1B(L17) cells in response to TGF-beta (data not shown).

RhoB mRNA Levels Are Unaffected by TGF-beta -- Growth factors such as epidermal growth factor and platelet-derived growth factor are known to increase the level of RhoB mRNA (16, 17). To address the possibility of changes in RhoB mRNA level, we examined the abundance of RhoB mRNA by both Northern hybridization of poly(A) RNA (Fig. 2A) and by RT-PCR (Fig. 2B). Mv1Lu cells were first incubated for 24 h in low serum medium to limit the potential confounding influences of serum components. Parallel cultures were then given a fresh aliquot of low serum medium with or without 40 pM TGF-beta and incubated for the indicated times. Northern analysis of poly(A) RNA using the RhoB cDNA as a probe yielded a single band of 2.6 kilobases characteristic of RhoB mRNA (16-18). As an internal control, we employed the 700-bp 1B15 probe specific for cyclophilin. Once again, a single band at 1 kilobases, characteristic of cyclophilin mRNA, was observed. The filter was probed sequentially with the RhoB and cyclophilin probes and analyzed by PhosphorImager. Fig. 2A demonstrates that RhoB mRNA levels are unchanged by TGF-beta throughout the 24-h exposure. Concerned that subtle changes in RhoB mRNA levels might be missed by direct hybridization, we employed RT-PCR to amplify subtle differences if they existed. Regions of absolute nucleotide conservation within the RhoB gene from rat to human and maximally divergent from other Rho family members were used to produce RhoB-specific primers. The identity of the predicted 304-bp RT-PCR product was confirmed by automated dideoxy sequencing (data not shown). Quantitation of the RhoB-specific RT-PCR product was normalized to GAPDH. As in Fig. 2A, the time course of RhoB mRNA levels in the presence and absence of TGF-beta was preceded by incubation in low serum medium. Consistent with the Northern hybridization, we observed no change in RhoB mRNA levels. Additionally, TGF-beta had no effect on luciferase reporter activity driven by a complete RhoB promoter (pGE-I, see "Materials and Methods"), which was inducible by 10% FBS (data not shown). These results suggested that the observed modulation of RhoB protein level induced by TGF-beta did not involve changes in the abundance of RhoB mRNA.


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 2.   RhoB accumulation in Mv1Lu cells in response to TGF-beta occurs without changes in mRNA levels. RhoB mRNA levels are unaffected by TGF-beta in Mv1Lu cells. Mv1Lu cells were maintained in DMEM + 0.2% FBS for 24 h. Cultures were then given a fresh aliquot of this same medium, with or without 40 pM TGF-beta . Poly(A) RNA (A) or total RNA (B) were prepared from parallel cultures after the indicated treatment durations. In A, 4 µg of poly(A) RNA was resolved in a 1% denaturing agarose gel, transferred to Hybond N+ membrane, and probed with the RhoB and cyclophilin cDNAs. In B, total RNA was reverse transcribed using an oligo(dT) primer. The resultant cDNA was amplified concurrently with RhoB- and GAPDH-specific primers. The GAPDH internal control and the predicted 304-bp RhoB-specific band are indicated. Parallel reactions, absent reverse transcriptase, showed no bands (data not shown).

TGF-beta Stabilizes RhoB Protein from Turnover by the 26 S Proteasome-- Regulation of protein stability has emerged as an important mechanism for controlling biological function (29). Labile proteins are excellent candidates for such regulation, because they can be rapidly increased in response to exogenous stimuli, yet their effects rapidly reversed by proteolysis. The short to intermediate half-life of RhoB suggests that its levels could be controlled by regulating its destruction. To address the stability of RhoB in the context of TGF-beta , we examined its fate in Mv1Lu cells in the presence and absence of TGF-beta using cycloheximide to abrogate new RhoB synthesis (Fig. 3). Parallel cultures of Mv1Lu cells were incubated for 4 h in low serum medium with or without 40 pM TGF-beta to create permissive environments characteristic of each treatment. Cells were then incubated in chase medium identical to the corresponding pretreatment mediums but supplemented with 30 µg/ml cycloheximide. At the times indicated, extracts of total protein were prepared and analyzed by alpha -RhoB immunoblot. Total RhoB signal was estimated by scanning densitometry and normalized to RhoB present at the start of the chase. In low serum medium, RhoB displays an apparent half-life between 60 and 90 min, consistent with previously published results (19). However, RhoB remains stable in the presence of TGF-beta . To confirm that RhoB detected during the chase reflected pre-existing protein rather than new RhoB synthesis, we subjected Mv1Lu cells to labeling with [35S]methionine/cysteine during the chase period either in the presence or in the absence of cycloheximide. RhoB protein synthesized during the chase was isolated by immunoprecipitation. Fig. 3C demonstrates that new RhoB synthesis was effectively abolished by cycloheximide. In concert, these data suggest that RhoB accumulation in response to TGF-beta reflects antagonism of the mechanisms required for its turnover.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   TGF-beta stabilizes RhoB protein in Mv1Lu cells. A, Mv1Lu cells were maintained in DMEM + 10% FBS. Cultures were pretreated (Pre-Tx) for 4 h in DMEM + 0.2% FBS in the presence or absence of TGF-beta . To initiate the chase, new protein synthesis was abrogated in each culture by the addition of cycloheximide. Cultures were then incubated for the indicated times, and cell extracts were prepared for RhoB-specific immunoblot analysis. Total RhoB signal in the presence and absence of TGF-beta for each time point was estimated by scanning densitometry and represented in the decay curves in B. C, to confirm abolition of new RhoB synthesis during the chase, 35S-labeled RhoB protein was immunoprecipitated (IP) from whole cell extracts prepared following a 4-h incubation in 100 µCi/ml [35S]methionine/cysteine either with or without coincident cycloheximide (CycHX) treatment. Both RhoB-specific antibody and normal rabbit serum (NRS) were employed.

RhoB Turnover Occurs via Ubiquitin-mediated Proteolysis-- The majority of protein turnover outside the lysosomal compartment occurs via the 26 S proteasome by ubiquitin-dependent proteolysis (29). To gain additional insights into the mechanism of RhoB turnover in Mv1Lu cells, we examined its conjugation to ubiquitin and its subsequent elimination by the 26 S proteasome. Mv1Lu cells were transiently transfected with expression constructs encoding HA-tagged RhoB (HA-RhoB) and octameric, hexahistidine-tagged ubiquitin (H6-ubiquitin), in the combinations shown in Fig. 4. Transfected cells were then incubated in the presence or the absence of 50 µM LLnL, an inhibitor of proteolysis by the 26 S proteasome. Ubiquitin-conjugated proteins were collected under denaturing conditions by Ni2+/NTA-agarose chromatography and subjected to SDS-PAGE and immunoblot analysis using either an alpha -RhoB or an alpha -HA antibody. These conditions permit detection of only covalent associations between ubiquitin and its targets. When 26 S proteasome activity is antagonized by LLnL, ubiquitinated forms of RhoB, confirmed by detection with both the RhoB- and HA-specific antibodies, are noted in cells transfected with both expression plasmids. No such bands are detected in mock transfected cells or in cells transfected only with a H6-ubiquitin expression construct. Electrophoretic mobilities of the ubiquitinated RhoB forms suggest that conjugation by one, two, and three ubiquitins could be easily discerned, whereas higher order conjugates were not resolved. The stabilization of RhoB in response to TGF-beta in conjunction with this data suggests that TGF-beta may exert negative regulatory influence toward some aspect of ubiquitin-mediated protein turnover by the 26 S proteasome.


View larger version (83K):
[in this window]
[in a new window]
 
Fig. 4.   Ubiquitinated RhoB is degraded by the 26 S proteasome in Mv1Lu cells. Mv1Lu cells were transiently transfected with H6-ubiquitin and HA-RhoB expression plasmids as shown. Each combination was subsequently incubated in the presence or absence of the proteasome inhibitor, LLnL. Ubiquitinated proteins were collected by Ni2+/NTA-agarose retrieval and subjected to immunoblot analysis with antibodies directed toward either RhoB or the HA tag of the transfected protein. Ubiquitinated forms of RhoB are indicated. Ubiquitin chain length estimates are based upon the apparent molecular weights of RhoB-Ubn conjugates in SDS-PAGE.

RhoB Antagonizes TGF-beta -mediated Transcriptional Activation-- Members of the Rho family can transactivate the TGF-beta -responsive promoter p3TP-Lux in a ligand-independent manner. To explore the impact of RhoB on TGF-beta signal transduction, we examined p3TP-Lux transactivation in Mv1Lu cells and their Tbeta RI deficient, TGF-beta -nonresponsive derivative, R1B(L17). Cells were transfected with p3TP-Lux reporter and either HA-RhoB or HA-RhoB-N19 expression plasmids as shown in Fig. 5. R1B(L17) cells were additionally transfected with a Tbeta RI expression plasmid to restore TGF-beta responsiveness. Luciferase activity in cell extracts was determined in the presence and absence of TGF-beta . Equivalent expression of HA-RhoB and HA-RhoB-N19 was confirmed by alpha -HA immunoblot analysis in Mv1Lu cells in a parallel experiment (data not shown). In both Mv1Lu and R1B(L17) cells, HA-RhoB antagonized TGF-beta -induced p3TP-Lux activation in a dose-dependent manner. HA-RhoB-N19 failed to attenuate TGF-beta -mediated p3TP-Lux activity in either Mv1Lu or R1B(L17) cells. These data suggest that RhoB GTPase function is required to inhibit TGF-beta -mediated transcriptional activation.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   RhoB antagonizes TGF-beta -mediated transcriptional activation. Mv1Lu or R1B(L17) cells were transfected as indicated. Tbeta RI expression in R1B cells restores responsiveness to TGF-beta . p3TP-Lux activity was measured in lysates prepared after incubation in DMEM + 0.2% FBS with or without 40 pM TGF-beta . Results are reported as means ± S.E. from triplicate analysis in a representative experiment. Luciferase data are normalized to internal control beta -galactosidase expression from a constitutive reporter. White bars, -TGF-beta ; black bars, +TGF-beta .

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The signal transduction machinery downstream of the TGF-beta receptor complex has been the focus of intense investigation. Considerable evidence suggests that Smad proteins are essential regulators of TGF-beta -mediated growth inhibition and transcriptional activation (3). However, recent data also suggest a critical role for Rho proteins in TGF-beta -mediated transcriptional activation (15). GTPase deficient, constitutively active mutants of RhoA, Rac1, and Cdc42Hs can transactivate the TGF-beta -responsive reporter p3TP-Lux in the absence of ligand. Additionally, Rac1 and to a lesser extent RhoA can potentiate the positive influence of TGF-beta on the same reporter. Dominant negative derivatives of Rac1, RhoA, and Cdc42Hs individually antagonized but collectively abolished TGF-beta -mediated transcriptional activation. Furthermore, dominant negative versions of MEKK1, MKK4, SAPK/JNK, and c-Jun, components of the SAPK/JNK pathway, each abolished the positive influences of constitutively active Rho proteins on p3TP-Lux transactivation. In concert, these results suggest that TGF-beta responsiveness may require the cooperation of the Rho/SAPK/JNK and Smad signal transduction cascades.

RhoB, like other members of the Ras superfamily, acts as a binary switch that cycles between GTP-bound (active) and GDP-bound (inactive) states. RhoB expression can be induced by a variety of stimuli, and evidence suggests that both RhoB mRNA and RhoB protein are labile, with half-lives of approximately 20 min and 2 h, respectively (18, 19). The inducibility and lability of RhoB, in conjunction with its post-translational modifications and its regulation by a bound guanine nucleotide, permit control of its function at several levels and as such present unique regulatory opportunities. We demonstrate that TGF-beta promotes the accumulation of isoprenylated RhoB by antagonizing its destruction. Interestingly, accumulation of RhoB in its isoprenylated form may reflect a connection between TGF-beta signaling and protein prenylation, suggested from the observed interaction of farnesyltransferase-alpha and the TGF-beta type I receptor (5). The ability of TGF-beta to regulate prenyltransferase activity toward RhoB is currently being explored. In contrast to other stimuli, we see no correlation between TGF-beta stimulation and the abundance of RhoB mRNA. Although this cannot be eliminated as a contributing factor, our data suggest that regulated RhoB turnover is primarily responsible for TGF-beta -induced RhoB accumulation. By extension, regulated protein stability might reflect a more general mechanism by which TGF-beta controls the activities of its downstream effectors to produce its diverse biological responses.

A small fraction of total cellular protein undergoes rapid turnover. Frequently these proteins are components of regulatory pathways. Their limited life span, in concert with other control mechanisms, provides restrictions on their biological influence. By extension, controlling the turnover rate of regulatory proteins, thereby influencing their steady-state levels, could dramatically affect signal transduction via the pathways in which these proteins participate. Several examples of controlled proteolysis as a means for regulating protein function have been described (29). The majority of selective protein turnover in eukaryotic cells is achieved by obligatory conjugation between lysine residues of the target protein and the C terminus of ubiquitin. Sequential ubiquitin additions yield multiubiquitin chains that direct the target protein for destruction by the 26 S proteasome (29). We show that RhoB protein is conjugated to ubiquitin in Mv1Lu cells and that ubiquitinated RhoB is subsequently eliminated by the 26 S proteasome. The participation of the 26 S proteasome and the coincident influence of TGF-beta on RhoB stability suggests that TGF-beta may regulate a component of the ubiquitin-dependent proteolytic machinery.

The reporter p3TP-Lux is frequently used as a measure of TGF-beta responsiveness in mammalian cells. To explore the influence of RhoB on TGF-beta signaling, we examined the impact of its expression or that of its dominant-negative mutant, RhoB-N19, on p3TP-Lux transactivation. In either Mv1Lu cells or R1B(L17) cells rendered TGF-beta -responsive by Tbeta RI cotransfection, wild type RhoB antagonized p3TP-Lux activation by TGF-beta . RhoB-N19 failed to attenuate and instead perhaps potentiated p3TP-Lux activity in these cells, consistent with dominant interference with endogenous RhoB function. These data suggest that RhoB exerts negative regulatory influence on TGF-beta -induced transcriptional activation. Functionally distinct negative regulation of TGF-beta signaling has also been described for FKBP12, Smad6, and Smad7 and correlated with binding to Tbeta RI. In light of the potentiating influence of other Rho family members toward p3TP-Lux transactivation and the labile nature of RhoB, it is attractive to speculate that RhoB accumulation in response to TGF-beta imposes negative but inherently self-limited restriction on the Rho-mediated aspects of TGF-beta signal transduction.

    ACKNOWLEDGEMENTS

We gratefully acknowledge Mary Aakre for technical assistance and Dr. George Prendergast, Dr. Joan Massagué, Dr. Mathias Trier, and Dr. Yoshiaki Monden for provision of reagents. Also, we thank Dr. Brian Law and Maureen McDonnell for critical reading of the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants CA42572 and CA48799.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Vanderbilt Cancer Center, 649 MRBII, Nashville, TN 37232-6838. Tel.: 615-936-1786; Fax: 615-936-1790; E-mail: hal.moses{at}MCmail.vanderbilt.edu.

1 The abbreviations used are: TGF-beta , transforming growth factor beta ; Tbeta RI, transmembrane serine/threonine kinase receptor type I; Tbeta RII, transmembrane serine/threonine kinase receptor type II; SAPK/JNK, stress-activated protein kinase/c-Jun N-terminal kinase; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; HA, hemagglutinin; LLnL, leucinyl-leucinyl-norleucinal; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; RT, reverse transcription; bp, base pair; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; NTA, nitrilotriacetic acid.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Lyons, R. M., and Moses, H. L. (1990) Eur. J. Biochem. 187, 467-473[Abstract]
  2. Massagué, J. (1996) Cell 85, 947-950[Medline] [Order article via Infotrieve]
  3. Massagué, J., Hata, A., and Liu, F. (1997) Trends Cell Biol. 7, 187-192[CrossRef]
  4. Wang, T., Li, B.-Y., Danielson, P. D., Shah, P. C., Rockwell, S., Lechleider, R. J., Martin, J., Manganaro, T., and Donahoe, P. K. (1996) Cell 86, 435-444[Medline] [Order article via Infotrieve]
  5. Kawabata, M., Imamura, T., Miyazona, K., Engel, M. E., and Moses, H. L. (1995) J. Biol. Chem. 270, 29628-29631[Abstract/Free Full Text]
  6. Chen, R.-H., Miettinen, P. J., Maruoka, E. M., Choy, L., and Derynck, R. (1995) Nature 377, 548-552[CrossRef][Medline] [Order article via Infotrieve]
  7. Van Aelst, L., and D'Souza-Schorey, C. (1997) Genes Dev. 11, 2295-2322[Free Full Text]
  8. Takai, Y., Sasaki, T., Tanaka, K., and Nakanishi, H. (1995) Trends Biochem. Sci. 20, 227-231[CrossRef][Medline] [Order article via Infotrieve]
  9. Lebowitz, P. F., Casey, P. J., Prendergast, G. C., and Thissen, J. A. (1997) J. Biol. Chem. 272, 15591-15594[Abstract/Free Full Text]
  10. Lebowitz, P. F., Du, W., and Prendergast, G. C. (1997) J. Biol. Chem. 272, 16093-16095[Abstract/Free Full Text]
  11. Ridley, A. J. (1995) Curr. Opin. Genet. Dev 5, 24-30[Medline] [Order article via Infotrieve]
  12. Olson, M. F., Ashworth, A., and Hall, A. (1995) Science 269, 1270-1272[Medline] [Order article via Infotrieve]
  13. Prendergast, G. C., Khosravi-Far, R., Solski, P. A., Kurzawa, H., Lebowitz, P. F., and Der, C. J. (1995) Oncogene 10, 2289-2296[Medline] [Order article via Infotrieve]
  14. Qui, R. G., Chen, J., McCormick, F., and Symons, M. (1996) Proc. Natl. Acad. Sci. U. S. A. 92, 11781-11785[Abstract]
  15. Atfi, A., Djelloul, S., Chastre, E., Davis, R., and Gespach, C. (1997) J. Biol. Chem. 272, 1429-1432[Abstract/Free Full Text]
  16. Jähner, D., and Hunter, T. (1991) Mol. Cell. Biol. 11, 3682-3690[Medline] [Order article via Infotrieve]
  17. De Cremoux, P., Gauville, C., Closson, V., Linares, G., Calvo, F., Tavitian, A., and Olofsson, B. (1994) Int. J. Cancer 59, 408-415[Medline] [Order article via Infotrieve]
  18. Fritz, G., Kaina, B., and Aktories, K. (1995) J. Biol. Chem. 270, 25172-25177[Abstract/Free Full Text]
  19. Lebowitz, P. F., Davide, J. P., and Prendergast, G. C. (1995) Mol. Cell. Biol. 15, 6613-6622[Abstract]
  20. Adamson, P., Marshall, C. J., Hall, A., and Tillbrook, P. A. (1992) J. Biol. Chem. 267, 20033-20038[Abstract/Free Full Text]
  21. Hill, C. S., and Treismann, R. (1995) Cell 80, 199-211[Medline] [Order article via Infotrieve]
  22. Flemming, I. N., Elliott, C. M., and Exton, J. H. (1996) J. Biol. Chem. 271, 33067-33073[Abstract/Free Full Text]
  23. Nakamura, T., Asano, M., Shindo-Okada, N., Nishimura, S., and Monden, Y. (1996) Biochem. Biophys. Res. Commun. 226, 688-694[CrossRef][Medline] [Order article via Infotrieve]
  24. Schägger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379[Medline] [Order article via Infotrieve]
  25. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, pp. 7.10-7.11 and 7.26-7.29, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  26. Chomzynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[CrossRef][Medline] [Order article via Infotrieve]
  27. Treier, M., Staszewski, L. M., and Bohmann, D. (1994) Cell 78, 787-798[Medline] [Order article via Infotrieve]
  28. Wrana, J. L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X.-F., and Massagué, J. (1992) Cell 71, 1003-1014[Medline] [Order article via Infotrieve]
  29. Hochstrasser, M. (1997) Annu. Rev. Genet. 30, 405-439[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.